Publications by authors named "J M P G M de Vos-Geelen"
Introduction: Adjuvant chemotherapy improves survival in patients with resected pancreatic ductal adenocarcinoma (PDAC). The decision to initiate chemotherapy involves both patient and physician factors, decision-specific criteria, and contextual considerations. This study aimed to assess medical oncologists' views on adjuvant chemotherapy following pancreatic resection for PDAC.
View Article and Find Full Text PDFArticle Synopsis
- - The study examined survival scenarios for pancreatic adenocarcinoma (PAC) patients over 16 years, highlighting best-case, typical, and worst-case survival estimates based on data from the Netherlands Cancer Registry.
- - Patients with localized PAC showed statistically significant improvements in best-case and typical survival scenarios, with gains averaging 1.54 and 0.24 months annually, respectively, while those with metastatic PAC experienced smaller but significant improvements.
- - Factors like age, aggressive treatments, and fewer comorbidities were linked to better survival outcomes, suggesting that recent advancements in care may offer hopeful prospects for PAC patients, despite small absolute survival gains.
Background: Patients with advanced-stage pancreatic ductal adenocarcinoma (PDAC) are regularly treated with FOLFIRINOX, a chemotherapy regimen based on 5-fluorouracil, irinotecan and oxaliplatin, which is associated with high toxicity. Dosing of FOLFIRINOX is based on body surface area, risking under- or overdosing caused by altered pharmacokinetics due to interindividual differences in body composition. This study aimed to investigate the relationship between body composition and treatment toxicity in advanced stage PDAC patients treated with FOLFIRINOX.
View Article and Find Full Text PDFIntroduction: The human gut microbiota influence critical functions including the metabolism of nutrients, xenobiotics, and drugs. Gut microbial β-glucuronidases (GUS) enzymes facilitate the removal of glucuronic acid from various compounds, potentially affecting anti-cancer drug efficacy and reactivating carcinogens. This review aims to comprehensively analyze and summarize studies on the role of gut microbial GUS in cancer and its interaction with anti-cancer treatments.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the interactions between the chemotherapy drug capecitabine (CAP) and gut microbiota in colorectal cancer patients, focusing on how these interactions may affect treatment side effects.
- Research involved a cohort of 56 patients, analyzing stool samples and using advanced sequencing techniques to observe changes in gut microbial composition during CAP treatment.
- Findings indicate that CAP alters gut bacteria, promoting genes related to vitamin K2 production, which appears to protect against drug toxicity, suggesting potential for microbiome profiling to predict chemotherapy side effects.